O5‐06‐02: OPTIMIZATION OF TISSUE‐SELECTIVE ABCA1 AGONISTS (TSAAGS) AS AN EFFECTIVE AND TOLERATED THERAPY FOR ALZHEIMER'S DISEASE. (1st July 2006)